Author

S. Ayeh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

D. Quijada· 2 shared P. Neupane· 2 shared S. Karanika· 2 shared S. Krug· 2 shared A. Garcia· 1 shared A. Sandhu· 1 shared A. Sher· 1 shared A. Yilma· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

D. Quijada

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model

J. Ruelas Castillo, P. Neupane, S. Karanika, S. Krug, D. Quijada, A. Garcia, S. Ayeh, A. Yilma, D. L. Costa, A. Sher, N. Fotouhi, N. Serbina, P. C. Karakousis

This paper evaluates the adjunctive effect of the HO-1 inhibitor stannsoporfin in combination with a novel MDR-TB regimen in a murine model, showing reduced lung bacillary burden but no effect on microbiological relapse.

bioRxiv · Aug 9, 2023Microbiology

An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

S. Karanika, J. Gordy, P. Neupane, T. KARANTANOS, J. Castillo, D. Quijada, K. Comstock, A. Sandhu, Y. Hui, S. Ayeh, R. Tasneen, S. Krug, C. Danchik, T. Wang, C. Schill, , P. Karakousis

This paper develops a DNA vaccine targeting dendritic cells that enhances isoniazid efficacy against tuberculosis by inducing strong immune responses and reducing Mtb burden.

bioRxiv · Apr 19, 2022Immunology